Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN versus MEFENAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN versus MEFENAMIC ACID.
Aspirin vs MEFENAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) via acetylation, reducing prostaglandin and thromboxane A2 synthesis. Also activates lipoxin biosynthesis (inflammation resolution).
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
325-650 mg PO q4-6h prn; max 4 g/day
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
None Documented
None Documented
30 minutes for aspirin (parent drug); salicylic acid: 2-3 hours after low doses, 15-30 hours after high doses due to saturable metabolism and renal reabsorption. Clinical context: prolonged half-life in overdose, renal impairment, and elderly patients.
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Renal excretion of salicylates (75-85% as salicyluric acid, 10% as free salicylic acid, 5-10% as glucuronide conjugates); dose-dependent, with renal clearance decreasing at higher doses due to saturation of metabolic pathways. Biliary/fecal elimination is minimal (<5%).
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Category C
Category D/X
NSAID / Antiplatelet
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."